Richard E. Valocik

474 total citations
18 papers, 365 citations indexed

About

Richard E. Valocik is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Richard E. Valocik has authored 18 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Cardiology and Cardiovascular Medicine and 4 papers in Internal Medicine. Recurrent topics in Richard E. Valocik's work include Blood Coagulation and Thrombosis Mechanisms (6 papers), Nitric Oxide and Endothelin Effects (4 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). Richard E. Valocik is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (6 papers), Nitric Oxide and Endothelin Effects (4 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). Richard E. Valocik collaborates with scholars based in United States, United Kingdom and Brazil. Richard E. Valocik's co-authors include Paul F. Koster, John R. Toomey, Gregory A. Kopia, John G. Gleason, Barry A. Berkowitz, Giora Feuerstein, Michael N. Blackburn, Andrew J. Nichols, M N Blackburn and G Feuerstein and has published in prestigious journals such as Stroke, Arteriosclerosis Thrombosis and Vascular Biology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Richard E. Valocik

18 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard E. Valocik United States 11 132 127 85 75 55 18 365
Emese Tóth-Zsámboki Hungary 12 255 1.9× 194 1.5× 37 0.4× 34 0.5× 118 2.1× 21 586
D George United States 7 266 2.0× 69 0.5× 30 0.4× 111 1.5× 129 2.3× 8 467
Nina Sarah Gowert Germany 9 70 0.5× 105 0.8× 17 0.2× 126 1.7× 71 1.3× 9 375
Artur-Aron Weber Germany 8 69 0.5× 64 0.5× 15 0.2× 34 0.5× 126 2.3× 8 446
Akikazu Takada Japan 9 34 0.3× 88 0.7× 26 0.3× 44 0.6× 74 1.3× 15 400
Xianyu Wang China 9 78 0.6× 250 2.0× 25 0.3× 19 0.3× 103 1.9× 17 504
Elizabeth K. Fletcher United States 11 98 0.7× 51 0.4× 11 0.1× 54 0.7× 121 2.2× 15 452
G. Pompella Italy 14 69 0.5× 46 0.4× 7 0.1× 59 0.8× 70 1.3× 18 402
Bastianina Zanda Italy 8 184 1.4× 27 0.2× 9 0.1× 42 0.6× 155 2.8× 10 435
Yoshihide Sehara Japan 9 64 0.5× 15 0.1× 14 0.2× 33 0.4× 162 2.9× 12 401

Countries citing papers authored by Richard E. Valocik

Since Specialization
Citations

This map shows the geographic impact of Richard E. Valocik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard E. Valocik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard E. Valocik more than expected).

Fields of papers citing papers by Richard E. Valocik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard E. Valocik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard E. Valocik. The network helps show where Richard E. Valocik may publish in the future.

Co-authorship network of co-authors of Richard E. Valocik

This figure shows the co-authorship network connecting the top 25 collaborators of Richard E. Valocik. A scholar is included among the top collaborators of Richard E. Valocik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard E. Valocik. Richard E. Valocik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Needle, Saul, Cynthia L. Burns-Kurtis, Richard E. Valocik, et al.. (2008). Antithrombotic Potential of GW813893: A Novel, Orally Active, Active-site Directed Factor Xa Inhibitor. Journal of Cardiovascular Pharmacology. 52(1). 66–71. 10 indexed citations
2.
Toomey, John R., Richard E. Valocik, Paul F. Koster, et al.. (2006). A comparison of the β‐D‐xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. Journal of Thrombosis and Haemostasis. 4(9). 1989–1996. 31 indexed citations
3.
Toomey, John R., James M. Samanen, Richard E. Valocik, et al.. (2002). The Antithrombotic Efficacy of Lotrafiban (SB 214857) in Canine Models of Acute Coronary Thrombosis. PubMed. 2(1). 13–25. 5 indexed citations
4.
Toomey, John R., Richard E. Valocik, Paul F. Koster, et al.. (2002). Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke. Stroke. 33(2). 578–585. 44 indexed citations
5.
Toomey, John R., Michael N. Blackburn, Barbara L. Storer, et al.. (2000). Comparing the Antithrombotic Efficacy of a Humanized Anti-factor IX(a) Monoclonal Antibody (SB 249417) to the Low Molecular Weight Heparin Enoxaparin In a Rat Model of Arterial Thrombosis. Thrombosis Research. 100(1). 73–79. 30 indexed citations
6.
Feuerstein, Giora, John R. Toomey, Peter J. Bugelski, et al.. (1999). Antithrombotic Efficacy of a Novel Murine Antihuman Factor IX Antibody in Rats. Arteriosclerosis Thrombosis and Vascular Biology. 19(10). 2554–2562. 63 indexed citations
7.
Feuerstein, G, John R. Toomey, Richard E. Valocik, et al.. (1999). An Inhibitory Anti-factor IX Antibody Effectively Reduces Thrombus Formation in a Rat Model of Venous Thrombosis. Thrombosis and Haemostasis. 82(11). 1443–1445. 41 indexed citations
8.
Parsons, Andrew A., et al.. (1998). Effects of the Novel Antimigraine Agent, Frovatriptan, on Coronary and Cardiac Function in Dogs. Journal of Cardiovascular Pharmacology. 32(6). 995–1000. 13 indexed citations
9.
Feuerstein, Giora, et al.. (1995). Cardioprotection and Thrombolysis by Anistreplase in Anesthetized Dogs. Journal of Cardiovascular Pharmacology. 25(4). 625–633. 2 indexed citations
10.
Nichols, Andrew J., Richard E. Valocik, Barbara L. Storer, et al.. (1994). The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. Thrombosis Research. 75(2). 143–156. 5 indexed citations
11.
Nichols, Andrew J., et al.. (1994). The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760.. PubMed. 270(2). 614–21. 7 indexed citations
12.
Nichols, Andrew J., et al.. (1994). The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760.. Journal of Pharmacology and Experimental Therapeutics. 270(2). 614–621. 1 indexed citations
13.
Hamburger, Steven A., et al.. (1991). A new model of myocardial infarction in yucatan minipigs. Journal of Pharmacological Methods. 25(4). 291–301. 4 indexed citations
14.
Kopia, Gregory A. & Richard E. Valocik. (1989). Demonstration of specific dopamine-1 receptor-mediated coronary vasodilation in the anesthetized dog.. Journal of Pharmacology and Experimental Therapeutics. 248(1). 215–221. 20 indexed citations
15.
Hieble, J. Paul, et al.. (1987). Hemodynamic Effects of Selective Dopamine Receptor Agonists in the Rat and Dog. Clinical and Experimental Hypertension Part A Theory and Practice. 9(5-6). 889–912. 14 indexed citations
16.
Kopia, Gregory A., Richard E. Valocik, T J Torphy, et al.. (1987). Inhibition of leukotriene D4-induced coronary vasoconstriction by leukotriene antagonists in the anesthetized dog.. Journal of Pharmacology and Experimental Therapeutics. 241(1). 174–180. 9 indexed citations
17.
Kopia, Gregory A. & Richard E. Valocik. (1985). Antagonism of Vasopressin-Induced Coronary Artery Constriction by the Vasopressin Antagonist d(CH2)5Tyr(Me)-AVP. Journal of Cardiovascular Pharmacology. 7(5). 958–963. 14 indexed citations
18.
Berkowitz, Barry A., et al.. (1984). Effects of the leukotrienes on the vasculature and blood pressure of different species.. Journal of Pharmacology and Experimental Therapeutics. 229(1). 105–112. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emese Tóth-Zsámboki Breakdown of academic impact, for papers by D George Breakdown of academic impact, for papers by Nina Sarah Gowert Breakdown of academic impact, for papers by Artur-Aron Weber Breakdown of academic impact, for papers by Akikazu Takada Breakdown of academic impact, for papers by Xianyu Wang Breakdown of academic impact, for papers by Elizabeth K. Fletcher Breakdown of academic impact, for papers by G. Pompella Breakdown of academic impact, for papers by Bastianina Zanda Breakdown of academic impact, for papers by Yoshihide Sehara
Rankless by CCL
2026